Clinical features of adverse reactions associated with telbivudine

被引:55
作者
Zhang, Xue-Song [1 ]
Jin, Rui [1 ]
Zhang, Shi-Bin [1 ]
Tao, Ming-Ling [1 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Dept GI & Hepatol, Beijing 100069, Peoples R China
关键词
adverse drug reaction; hepatitis B; mitochondria; nucleoside analogue; telbivudine;
D O I
10.3748/wjg.14.3549
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To analyze the clinical features and risk factors of adverse reactions associated with telbivudine. METHODS: Clinical data were collected from cases that presented with serious adverse reactions to telbivudine. We analyzed general information and medicine status, clinical features, results of examination, and misdiagnosis. RESULTS: Out of 105 patients who were treated with telbivudine for hepatitis B in an outpatient department from January, 2007 to January, 2008, five presented with serious adverse drug reactions. Most of these five patients had used other nucleoside analogues in the past. Four were treated with a combination of telbivudine and interferon or another nucleoside analogue, while the other received an increased dose of telbivudine. The main adverse reactions were myalgia and general weakness. This was accompanied by cardiac arrhythmia in one patient, and nervous symptoms in three. Serum creatine kinase was elevated. The rate of misdiagnosis was high. CONCLUSION: The adverse reactions were related to telbivudine, but the biological mechanism of the reactions is not yet clear. Combination therapy with interferon or another nucleoside analogue and a high dose may increase the risk of adverse reactions. (C) 2008 The WJG Press. All rights reserved.
引用
收藏
页码:3549 / 3553
页数:5
相关论文
共 31 条
[1]
Treating chronic hepatitis B: Today and tomorrow [J].
Borgia, G. ;
Gentile, I. .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (23) :2839-2855
[2]
Antiviral L-nucleosides specific for hepatitis B virus infection [J].
Bryant, ML ;
Bridges, EG ;
Placidi, L ;
Faraj, A ;
Loi, AG ;
Pierra, C ;
Dukhan, D ;
Gosselin, G ;
Imbach, JL ;
Hernandez, B ;
Juodawlkis, A ;
Tennant, B ;
Korba, B ;
Cote, P ;
Marion, P ;
Cretton-Scott, E ;
Schinazi, RF ;
Sommadossi, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :229-235
[3]
Treatment of hepatitis B e antigen - Positive chronic hepatitis with telbivudine or adefovir [J].
Chan, Henry L. Y. ;
Heathcote, E. Jenny ;
Marcellin, Patrick ;
Lai, Ching-Lung ;
Cho, Mong ;
Moon, Young M. ;
Chao, You-Chen ;
Myers, Robert P. ;
Minuk, Gerald Y. ;
Jeffers, Lennox ;
Sievert, William ;
Bzowej, Natalie ;
Harb, George ;
Kaiser, Ralf ;
Qiao, Xin-Jian ;
Brown, Nathaniel A. .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (11) :745-U14
[4]
CHEN QT, 1994, ZHONGGUO SHENJING JI, V20, P16
[5]
DENG AP, 2005, ZHONGGUO XINYAO YU L, V4, P326
[6]
Relationship between antiviral activity and host toxicity:: Comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase [J].
Feng, JY ;
Murakami, E ;
Zorca, SM ;
Johnson, AA ;
Johnson, KA ;
Schinazi, RF ;
Furman, PA ;
Anderson, KS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1300-1306
[7]
Advances in the treatment of hepatitis B [J].
Ferreira, Marcelo Simao ;
Borges, Aercio Sebastiao .
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2007, 40 (04) :451-462
[8]
FU ZX, 2000, HENAN YIKE DAXUE XUE, V35, P451
[9]
GU CH, 2000, ANTIVIRUS THERAPY NU, P396
[10]
THE MITOCHONDRIAL-DNA TRANSFER RNA(LYS) A-]G(8344) MUTATION AND THE SYNDROME OF MYOCLONIC EPILEPSY WITH RAGGED-RED FIBERS (MERRF) - RELATIONSHIP OF CLINICAL PHENOTYPE TO PROPORTION OF MUTANT MITOCHONDRIAL-DNA [J].
HAMMANS, SR ;
SWEENEY, MG ;
BROCKINGTON, M ;
LENNOX, GG ;
LAWTON, NF ;
KENNEDY, CR ;
MORGANHUGHES, JA ;
HARDING, AE .
BRAIN, 1993, 116 :617-632